Malmö, Sweden

Emma Salomonsson

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Emma Salomonsson: Innovator in Metabolic Disorder Treatments

Introduction

Emma Salomonsson is a prominent inventor based in Malmö, Sweden. She has made significant contributions to the field of metabolic disorders through her innovative research and development. Her work focuses on creating solutions that can improve the health and well-being of patients suffering from these conditions.

Latest Patents

Emma holds a patent for a synthetic composition designed for treating metabolic disorders. This invention involves a synthetic composition that comprises one or more human milk monosaccharides and/or one or more human milk oligosaccharides. The primary use of this composition is to reduce intestinal permeability, endotoxemia, and low-grade inflammation in patients with metabolic disorders. This patent highlights her commitment to advancing medical science and improving patient outcomes.

Career Highlights

Emma is currently employed at Glycom A/S, a company known for its focus on human milk oligosaccharides and their applications in health. Her role at Glycom A/S allows her to collaborate with other experts in the field and contribute to groundbreaking research.

Collaborations

Emma has worked alongside notable colleagues such as Bruce McConnell and Thierry Hennet. These collaborations have further enriched her research and have led to advancements in the understanding and treatment of metabolic disorders.

Conclusion

Emma Salomonsson is a trailblazer in the field of metabolic disorder treatments, with her innovative patent showcasing her dedication to improving health outcomes. Her work at Glycom A/S and collaborations with esteemed colleagues underline her impact on the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…